A shift from nuclear to cytoplasmic breast cancer metastasis suppressor 1 expression is associated with highly proliferative estrogen receptor-negative breast cancers

Tumor Biology

Volumn 30, Issue 3, 2009, Pages 148-159

  Frolova, Natalya ^a   Edmonds, Mick D ^a   Bodenstine, Thomas M ^a   Seitz, Robert ^f   Johnson, Martin R ^b,e   Feng, Rui ^d   Welch, Danny R ^a,b,c,d,e   Frost, Andra R ^a,c,e  

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f Applied Genomics Inc   (United States)

Author keywords

Breast cancer metastasis suppressor 1; Breast cancer progression; Immunohistochemistry; Prognosis

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1B; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; MESSENGER RNA; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST CANCER METASTASIS SUPPRESSOR 1 GENE; BREAST EPITHELIUM; CANCER SURVIVAL; CARBOXY TERMINAL SEQUENCE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOPLASM; EPITHELIUM CELL; GENE EXPRESSION; GENE LOCATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LASER CAPTURE MICRODISSECTION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TISSUE MICROARRAY; TUMOR SUPPRESSOR GENE;

EID: 67650468148     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1159/000228908     Document Type: Article

References (58)

1. Stafford LJ, Vaidya KS, Welch DR: Metastasis suppressors genes in cancer. Int J Biochem Cell Biol 2008;40:874-891.
2. Seraj MJ, Samant RS, Verderame MF, Welch DR: Functional evidence for a novel human breast carcinoma metastasis suppressor, BRMS1, encoded at chromosome 11q13. Cancer Res 2000;60:2764-2769.
3. Hurst DR, Xie Y, Vaidya KS, Mehta A, Moore BP, Accavitti-Loper MA, Samant RS, Saxena R, Silveira AC, Welch DR: Alterations of BRMS1-ARID4A interaction modify gene expression but still suppress metastasis in human breast cancer cells. J Biol Chem 2008;283:7438-7444.
4. Meehan WJ, Samant RS, Hopper JE, Carrozza MJ, Shevde LA, Workman JL, Eckert KA, Verderame MF, Welch DR: Breast cancer metastasis suppressor 1 (BRMS1) forms complexes with retinoblastoma-binding protein 1 (RBP1) and the mSin3 histone deacetylase complex and represses transcription. J Biol Chem 2004;279:1562-1569.
5. Vaidya KS, Harihar S, Stafford LJ, Hurst DR, Hicks DG, Casey G, DeWald DB, Welch DR: Breast cancer metastasis suppressor-1 differentially modulates growth factor signaling. J Biol Chem 2008;283:28354-28360.
6. DeWald DB, Torabinejad J, Samant RS, Johnston D, Erin N, Shope JC, Xie Y, Welch DR: Metastasis suppression by breast cancer metastasis suppressor 1 involves reduction of phosphoinositide signaling in MDA-MB-435 breast carcinoma cells. Cancer Res 2005;65:713-717. (Pubitemid 40216427)
7. Cicek M, Fukuyama R, Welch DR, Sizemore N, Casey G: Breast cancer metastasis suppressor 1 inhibits gene expression by targeting nuclear factor-kB activity. Cancer Res 2005;65:3586-3595. (Pubitemid 40616334)
8. Liu Y, Smith PW, Jones DR: Breast cancer metastasis suppressor 1 functions as a corepressor by enhancing histone deacetylase 1-mediated deacetylation of RelA/p65 and promoting apoptosis. Mol Cell Biol 2006;26:8683-8696. (Pubitemid 44851930)
9. Hedley BD, Welch DR, Allan AL, Al-Katib W, Dales DW, Postenka CO, Casey G, MacDonald IC, Chambers AF: Downregulation of osteopontin contributes to metastasis suppression by breast cancer metastasis suppressor 1. Int J Cancer 2008;123:526-534. (Pubitemid 351898409)
10. Shevde LA, Samant RS, Paik JC, Metge BJ, Chambers AF, Casey G, Frost AR, Welch DR: Osteopontin knockdown suppresses tumorigenicity of human metastatic breast carcinoma. Clin Exp Metastasis 2006;23:123-133. (Pubitemid 44440172)
11. Samant RS, Clark DW, Fillmore RA, Cicek M, Metge BJ, Chandramouli KH, Chambers AF, Casey G, Welch DR, Shevde LA: Breast cancer metastasis suppressor 1 (BRMS1) inhibits osteopontin transcription by abrogating NF-kappaB activation. Mol Cancer 2007;6:6. (Pubitemid 46243445)
12. Kapoor P, Saunders MM, Li Z, Zhou Z, Schaeffer N, Kunze EL, Samant RS, Welch DR, Donahue HJ: Breast cancer metastatic potential: correlation with increased heterotypic gap junctional intercellular communication between breast cancer cells and osteoblastic cells. Int J Cancer 2004;111:693-697. (Pubitemid 39062890)
13. Shevde LA, Samant RS, Goldberg SF, Sikaneta T, Alessandrini A, Donahue HJ, Mauger DT, Welch DR: Suppression of human melanoma metastasis by the metastasis suppressor gene, BRMS1. Exp Cell Res 2002;273:229-239. (Pubitemid 34920673)
14. Saunders MM, Seraj MJ, Li ZY, Zhou ZY, Winter CR, Welch DR, Donahue HJ: Breast cancer metastatic potential correlates with a breakdown in homospecific and heterospecific gap junctional intercellular communication. Cancer Res 2001;61:1765-1767.
15. Hurst DR, Edmonds MD, Scott GK, Benz CC, Vaidya KS, Welch DR: Breast cancer metastasis suppressor 1 up-regulates miR-146, which suppresses breast cancer metastasis. Cancer Res 2009;69:1279-1283.
16. Champine PJ, Michaelson J, Weimer B, Welch DR, DeWald DB: Microarray analysis reveals potential mechanisms of BRMS1-mediated metastasis suppression. Clin Exp Metastasis 2007;24:551-565.
17. Rivera J, Megias D, Bravo J: Proteomics-based strategy to delineate the molecular mechanisms of the metastasis suppressor gene BRMS1. J Proteome Res 2007;6:4006-4018. (Pubitemid 350032564)
18. Cicek M, Samant RS, Kinter M, Welch DR, Casey G: Identification of metastasis-associated proteins through protein analysis of metastatic MDA-MB-435 and metastasis-suppressed BRMS1 transfected-MDA-MB-435 cells. Clin Exp Metastasis 2004;21:149-157. (Pubitemid 38988088)
19. Eccles SA, Welch DR: Metastasis: recent discoveries and novel treatment strategies. Lancet 2007;369:1742-1757. (Pubitemid 46755391)
20. Lombardi G, Di Cristofano C, Capodanno A, Iorio MC, Aretini P, Isola P, Tancredi M, Collecchi P, Naccarato AG, Porta RP, Bevilacqua G, Caligo MA: High level of messenger RNA for BRMS1 in primary breast carcinomas is associated with poor prognosis. Int J Cancer 2006;120:1169-1178. (Pubitemid 46256769)
21. Kelly LM, Buggy Y, Hill A, O'Donovan N, Duggan C, McDermott EW, O'Higgins NJ, Young L, Duffy MJ: Expression of the breast cancer metastasis suppressor gene, BRMS1, in human breast carcinoma: lack of correlation with metastasis to axillary lymph nodes. Tumor Biol 2005;26:213-216. (Pubitemid 41379748)
22. Ohta S, Lai EW, Pang ALY, Brouwers FM, Chan WY, Eisenhofer G, deKrijger R, Ksinantova L, Breza J, Blazicek P, Kvetnansky R, Wesley RA, Pacak K: Downregulation of metastasis suppressor genes in malignant pheochromocytoma. Int J Cancer 2005;114:139-143.
23. Kaushik N, Fear D, Richards SC, McDermott CR, Nuwaysir EF, Kellam P, Harrison TJ, Wilkinson RJ, Tyrrell DA, Holgate ST, Kerr JR: Gene expression in peripheral blood mononuclear cells from patients with chronic fatigue syndrome. J Clin Pathol 2005;58:826-832. (Pubitemid 41113389)
24. Zhang Z, Yamashita H, Toyama T, Yamamoto Y, Kawasoe T, Iwase H: Reduced expression of the breast cancer metastasis suppressor 1 mRNA is correlated with poor progress in breast cancer. Clin Cancer Res 2006;12:6410-6414. (Pubitemid 44799712)
25. Hurst DR, Xie Y, Edmonds MD, Welch DR: Multiple forms of BRMS1 are differentially expressed in the MCF10 isogenic breast cancer progression model. Clin Exp Metastasis 2009;26:89-96.
26. Hurst DR, Mehta A, Moore BP, Phadke PA, Meehan WJ, Accavitti MA, Shevde LA, Hopper JE, Xie Y, Welch DR, Samant RS: Breast cancer metastasis suppressor 1 (BRMS1) is stabilized by the Hsp90 chaperone. Biochem Biophys Res Commun 2006;348:1429-1435. (Pubitemid 44291357)
27. Hicks DG, Yoder BJ, Short S, Tarr S, Prescott N, Crowe JP, Dawson AE, Budd GT, Sizemore S, Cicek M, Choueiri T, Tubbs RR, Gaile D, Nowak N, Accavitti-Loper MA, Frost AR, Welch DR, Casey G: Loss of BRMS1 protein expression predicts reduced disease-free survival in hormone receptor negative and HER2 positive subsets of breast cancer. Clin Cancer Res 2006;12:6702-6708. (Pubitemid 44876838)
28. Smith PW, Liu Y, Siefert SA, Moskaluk CA, Petroni GR, Jones DR: Breast cancer metastasis suppressor 1 (BRMS1) suppresses metastasis and correlates with improved patient survival in non-small cell lung cancer. Cancer Lett 2009;276:196-203.
29. Silveira AC, Hurst DR, Vaidya KS, Ayer DE, Welch DR: Over-expression of the BRMS1 family member SUDS3 does not suppress metastasis of human cancer cells. Cancer Lett 2009;276:32-37.
30. Blanquicett C, Johnson MR, Heslin M, Diasio RB: Housekeeping gene variability in normal and carcinomatous colorectal and liver tissues: applications in pharmacogenomic gene expression studies. Anal Biochem 2002;303:209-214. (Pubitemid 34407587)
31. Talley L, Chhieng DC, Bell WC, Grizzle WE, Frost AR: Immunohistochemical detection of EGFR, p185(erbB-2), Bcl-2 and p53 in breast carcinomas in pre-menopausal and post-menopausal women. Biotech Histochem 2008;83:5-14.
32. Talley LI, Grizzle WE, Waterbor JW, Brown D, Weiss H, Frost AR: Hormone receptors and proliferation in breast carcinomas of equivalent histologic grades in pre- and postmenopausal women. Int J Cancer 2002;98:118-127. (Pubitemid 34113428)
33. Grizzle WE, Myers RB, Manne U, Stockard CR, Harkins LE, Srivastava S: Factors affecting immunohistochemical evaluation of biomarker expression in neoplasia; in Hanausek M, Walaszek Z (eds): John Walker's Methods in Molecular Medicine - Tumor Marker Protocols. Totowa, Humana Press, 1998, pp 161-179.
34. Frost AR, Sparks D, Grizzle WE: Methods of antigen recovery vary in their usefulness in unmasking specific antigens in immunohistochemistry. Appl Immunohistochem Mol Morphol 2000;8:236-243. (Pubitemid 30677911)
35. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
36. Cox D: Regression models and life tables. J R Stat Soc 1972;34:187-220.
37. Pichon MF, Broet P, Magdelenat H, Delarue JC, Spyratos F, Basuyau JP, Saez S, Rallet A, Courriere P, Millon R, Asselain B: Prognostic value of steroid receptors after long-term follow-up of 2257 operable breast cancers. Br J Cancer 1996;73:1545-1551. (Pubitemid 26235381)
38. Fisher B, Redmond C, Fisher ER, Caplan R: Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06. J Clin Oncol 1988;6:1076-1087.
39. Zellars RC, Hilsenbeck SG, Clark GM, Allred DC, Herman TS, Chamness GC, Elledge RM: Prognostic value of p53 for local failure in mastectomy-treated breast cancer patients. J Clin Oncol 2000;18:1906-1913. (Pubitemid 30261928)
40. Stefano R, Agostara B, Calabro M, Campisi I, Ravazzolo B, Traina A, Miele M, Castagnetta L: Expression levels and clinical-pathological correlations of HER2/neu in primary and metastatic human breast cancer. Ann NY Acad Sci 2004;1028:463-472. (Pubitemid 40361848)
41. Barbareschi M, Doglioni C, Veronese S, Bonzanini M, Dalla PP, Harris AL, Caffo O: p21WAF1 and p53 immunohistochemical expression in breast carcinoma may predict therapeutic response to adjuvant treatment. Eur J Cancer 1996;32A:2182-2183. (Pubitemid 26419472)
42. Barbareschi M, Caffo O, Veronese S, Leek RD, Fina P, Fox S, Bonzanini M, Girlando S, Morelli L, Eccher C, Pezzella F, Doglioni C, Dalla PP, Harris A: Bcl-2 and p53 expression in node-negative breast carcinoma: a study with long-term follow-up. Hum Pathol 1996;27:1149-1155. (Pubitemid 26374933)
43. Barbareschi M, Caffo O, Doglioni C, Fina P, Marchetti A, Buttitta F, Leek R, Morelli L, Leonardi E, Bevilacqua G, Dalla PP, Harris AL: p21WAF1 immunohistochemical expression in breast carcinoma: correlations with clinicopathological data, oestrogen receptor status, MIB1 expression, p53 gene and protein alterations and relapse-free survival. Br J Cancer 1996;74:208-215. (Pubitemid 126732895)
44. Jalava PJ, Collan YU, Kuopio T, Juntti-Patinen L, Kronqvist P: Bcl-2 immunostaining: a way to finding unresponsive postmenopausal N+ breast cancer patients. Anticancer Res 2000;20:1213-1219. (Pubitemid 30240703)
45. Nakopoulou LL, Alexiadou A, Theodoropoulos GE, Lazaris AC, Tzonou A, Keramopoulos A: Prognostic significance of the coexpression of p53 and c-erbB-2 proteins in breast cancer. J Pathol 1996;179:31-38. (Pubitemid 26180083)
46. Horita K, Yamaguchi A, Hirose K, Ishida M, Noriki S, Imamura Y, Fukuda M: Prognostic factors affecting disease-free survival rate following surgical resection of primary breast cancer. Eur J Histochem 2001;45:73-84. (Pubitemid 33654603)
47. Van Diest PJ, van der Wall E, Baak JP: Prognostic value of proliferation in invasive breast cancer: a review. J Clin Pathol 2004;57:675-681. (Pubitemid 38901478)
48. Barbareschi M, van Tinteren H, Mauri FA, Veronese S, Peterse H, Maisonneuve P, Caffo O, Scaioli M, Doglioni C, Galligioni E, Dalla Palma P, Michalides R: P27Kip1 expression in breast carcinomas: an immunohistochemical study on 512 patients with long-term follow-up. Int J Cancer 2000;89:236-241. (Pubitemid 30430739)
49. Tsuchiya A, Zhang GJ, Kanno M: Prognostic impact of cyclin-dependent kinase inhibitor p27kip1 in node-positive breast cancer. J Surg Oncol 1999;70:230-234. (Pubitemid 29187908)
50. Kielhorn E, Provost E, Olsen D, D'Aquila TG, Smith BL, Camp RL, Rimm DL: Tissue microarray-based analysis shows phospho-β-catenin expression in malignant melanoma is associated with poor outcome. Int J Cancer 2003;103:652-656. (Pubitemid 36091470)
51. Johnson JP: Cell adhesion molecules in the development and progression of malignant melanoma. Cancer Metastasis Rev 1999;18:345-357. (Pubitemid 30104068)
52. Nakopoulou L, Mylona E, Papadaki I, Kavantzas N, Giannopoulou I, Markaki S, Keramopoulos A: Study of phospho-beta-catenin subcellular distribution in invasive breast carcinomas in relation to their phenotype and the clinical outcome. Mod Pathol 2006;19:556-563.
53. Narahashi T, Niki T, Wang T, Goto A, Matsubara D, Funata N, Fukayama M: Cytoplasmic localization of p63 is associated with poor patient survival in lung adenocarcinoma. Histopathology 2006;49:349-357. (Pubitemid 44401541)
54. Ohata M, Nakamura S, Fujita H, Isemura M: Prognostic implications of p21 (Waf1/Cip1) immunolocalization in multiple myeloma. Biomed Res 2005;26:91-98. (Pubitemid 41519981)
55. Singh SP, Lipman J, Goldman H, Ellis FHJ, Aizenman L, Cangi MG, Signoretti S, Chiaur DS, Pagano M, Loda M: Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma. Cancer Res 1998;58:1730-1735. (Pubitemid 28215101)
56. Ogino S, Kawasaki T, Ogawa A, Kirkner GJ, Loda M, Fuchs CS: Cytoplasmic localization of p27 (cyclin-dependent kinase inhibitor 1B/KIP1) in colorectal cancer: inverse correlations with nuclear p27 loss, microsatellite instability, and CpG island methylator phenotype. Hum Pathol 2007;38:585-592. (Pubitemid 46399885)
57. Sembritzki O, Hagel C, Lamszus K, Deppert W, Bohn W: Cytoplasmic localization of wild-type p53 in glioblastomas correlates with expression of vimentin and glial fibrillary acidic protein. Neuro Oncol 2002;4:171-178. (Pubitemid 35214753)
58. Metge BJ, Frost AR, King JA, Dyess DL, Welch DR, Samant RS, Shevde LA: Epigenetic silencing contributes to the loss of BRMS1 expression in breast cancer. Clin Exp Metastasis 2008;25:753-763.